ArticlemedRxiv : the preprint server for health sciences2025
Deciphering rifampicin resistance among tuberculosis patients who have trace results on Xpert MTB/RIF ultra assay.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Introduction: The Methods: Four hundred and three (403) MTB detected trace, RIF resistance indeterminate results, which were obtained in Mycobacteriology (BSL-3) and Molecular Diagnostic laboratories, College of Health Sciences, Makerere University from August 2018 to June 2023, having culture results were identified from the laboratory database. Isolates of those that turned out culture positive were retrieved and sub-cultured in liquid media to perform phenotypic first line Drug Susceptibility tests, first line Line-Probe assays (LPA) and repeat GeneXpert ultra. Results: A total of 31/403 (7.7%) culture positive isolates were identified from the database of which 77.42% (24/31) were positive for Conclusion: In this study, we did not identify any missed rifampicin resistance among MTBc culture positive samples that were initially Xpert ultra-trace and rifampicin resistance indeterminate. More studies with bigger sample sizes especially in high MDR-TB settings are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.